Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
100%
Tablet
68%
Budesonide
51%
Infliximab
34%
Good Manufacturing Practice
32%
Acetylsalicylic Acid
28%
Hospital Pharmacy
28%
Aminosalicylic Acid
20%
Sustained Release
18%
Dosage Forms
17%
Tumor Necrosis Factor
16%
Ulcerative Colitis
14%
Phosphotransferase Inhibitor
14%
Therapeutic Drug Monitoring
14%
Xerostomia
14%
Riboflavin
14%
Neoplasm
14%
Head and Neck Cancer
14%
Suppository
14%
Non Small Cell Lung Cancer
14%
Phase II Trials
14%
Ascorbic Acid
14%
Nicotinamide
14%
Guanosine Phosphate
14%
Crohn's Disease
13%
Drug Release
11%
Ileum
11%
Inflammation
10%
Malignant Neoplasm
9%
High Performance Liquid Chromatography
8%
Disease
8%
Adverse Event
7%
Antiinflammatory Agent
7%
Nicotinic Acid
7%
Particle-Size Distribution
7%
Microbiome
7%
Novel Formulation
6%
Keyphrases
Production Process
28%
Inflammatory Bowel Disease
28%
Good Manufacturing Practice
23%
Clinical Practice
17%
Gut Health
14%
Health Development
14%
Human Plasma
14%
Budesonide
14%
Kinase Inhibitor
14%
Pharmaceutical Water
14%
Rapid Quantification
14%
Targeted Release
14%
Clinical Grade
14%
Vitamin B3
14%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
14%
Human Serum
14%
Vitamin C
14%
Vitamin B2
14%
Cell Therapy
14%
Vitamins
14%
Therapeutic Drug Monitoring
14%
Parotid Salivary Gland
14%
Radiation-induced Xerostomia
14%
Tumor Necrosis Factor-α
14%
Head-and-neck Cancer
14%
Salivary Gland Organoids
14%
Visualization Study
14%
Simultaneous Quantification
14%
ColoPulse
14%
Tumor Neoantigens
14%
Zero-order Release
14%
Parenteral Drug Products
14%
Pharmacy Compounding
14%
Qualification Test
14%
Practice Conditions
14%
Hospital Pharmacy
14%
Visual Inspection
14%
Inspection Technique
14%
Zero-order Release Kinetics
9%
Salivary Gland
9%
Manufacturing Process
9%
Simulation System
9%
Site-specific Release
9%
Literature Search
8%
Clinical Applicability
7%
Entocort
7%
Budesonide MMX
7%
Cortiment
7%
Tumour Necrosis Factor Inhibitor (TNFi)
7%
Qualification Method
7%
Medicine and Dentistry
Inflammatory Bowel Disease
42%
Gastrointestinal Tract
16%
Tumor Necrosis Factor
16%
Head and Neck Cancer
14%
Infliximab
14%
Cell Therapy
14%
Salivary Gland
14%
Budesonide
14%
Sustained Drug Release
14%
Organoid
14%
Mesalazine
14%
Xerostomia
14%
Hospital Pharmacy
14%
Guanosine Phosphate
14%
Ulcerative Colitis
6%